Valbenazine, sold under the brand name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 inhibitor. As a valproate-derived prodrug, valbenazine is converted in vivo to an active metabolite that binds selectively and reversibly to VMAT2 in presynaptic neurons, reducing vesicular dopamine uptake and thereby lowering synaptic dopamine availability that contributes to involuntary hyperkinetic movements; the product is formulated for once-daily oral dosing, undergoes hepatic biotransformation with contributions from CYP3A and CYP2D6 pathways, and is characterized by high chemical and enantiomeric purity with routine quality control by HPLC, LC-MS and chiral analysis.
Parent: Valbenazine
![(2S,3S,11bS)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol](https://veeprho.com/wp-content/uploads/2026/04/2S3S11bS-3-Isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-ol-164104-49-8-VE0028700.png "(2S,3S,11bS)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol")
Parent: Tetrabenazine/ Valbenazine
![(2S,3S,11bS)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate](https://veeprho.com/wp-content/uploads/2026/04/2S3S11bS-3-Isobutyl-910-dimethoxy-1346711b-hexahydro-2H-pyrido21-aisoquinolin-2-yl-L-valinate-NA-VE0028699.png "(2S,3S,11bS)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate")
Parent: Valbenazine
Drug substance specifications typically control related substances and degradation products tightly to ensure safety and stability, with individual unspecified impurities commonly limited to 0.10% w/w or less and total impurities controlled to 0.50% w/w or less; identified related compounds frequently monitored include an N-oxide oxidation product (Impurity A) at a specification maximum of 0.05% w/w, a dealkylation product (Impurity B) at 0.03% w/w, a hydrolytic cleavage product (Impurity C) at 0.02% w/w, and trace-level synthesis-related precursors maintained below reporting thresholds, all quantified by validated HPLC-UV methods and confirmed by LC-MS, with residual solvents and metal catalysts tested per ICH guidelines.
Valbenazine works by selectively and reversibly inhibiting the vesicular monoamine transporter 2 VMAT2, which decreases the transport of monoamines into synaptic vesicles and reduces presynaptic dopamine release, thereby lowering synaptic dopamine concentrations that drive the involuntary movements of tardive dyskinesia.
Valbenazine is metabolized in the liver to an active metabolite through pathways involving CYP3A and CYP2D6 isoenzymes; because of these pathways, coadministration with strong CYP3A inhibitors or CYP2D6 poor metabolizer status can increase active exposure and may require dose adjustment or monitoring, whereas routine dosing is once daily with established titration regimens in the product labeling.
Manufacturing and quality control typically monitor identified related substances such as oxidation products, dealkylation products and hydrolysis products with individual impurity limits around 0.05% to 0.10% w/w and a total impurities limit around 0.50% w/w, using validated HPLC and LC-MS methods; specific limits are set in the product specification and validated stability protocol for each batch.
